confocal laser scanning microscopy

Stages

1. 1.
   Antibacterial activity profiling by MIC and MBC(broad_screen)

   This stage identifies which sphingolipids and ceramide analogs are active against pathogenic Neisseria and distinguishes them from compounds inactive against comparator bacteria.

   Selection: Compounds showing antibacterial activity against Neisseria meningitidis and N. gonorrhoeae in MIC and MBC assays.

2. 2.
   Kinetic killing characterization(secondary_characterization)

   This stage characterizes the time scale of bactericidal action for an active compound after initial activity has been established.

   Selection: Measure how quickly an active compound kills N. meningitidis.

3. 3.
   Host-cell toxicity check(confirmatory_validation)

   This stage checks whether antibacterial activity is accompanied by significant toxicity to host cells.

   Selection: Assess whether bactericidal concentrations cause significant host-cell toxicity.

4. 4.
   Bacterial uptake and membrane localization imaging(functional_characterization)

   This stage provides spatial and temporal evidence that ceramide analogs enter bacteria rapidly and distribute in the bacterial membrane.

   Selection: Visualize uptake timing and membrane distribution of ceramide analogs in bacteria.

Steps

1. 1.
   Measure MIC and MBC of sphingolipids and ceramide analogs against pathogenic Neisseria and comparator bacteriatested antibacterial ceramide analog

   Identify active compounds and assess organism selectivity.

   Initial potency testing is needed before kinetic, toxicity, and localization follow-up can focus on active compounds.

2. 2.
   Test killing kinetics of ω-azido-C6-ceramide against Neisseria meningitidisactive hit selected for kinetic follow-up

   Determine how rapidly the active compound kills bacteria.

   Kinetic characterization follows initial activity detection to refine understanding of bactericidal performance.

3. 3.
   Assess host-cell toxicity of ω-azido-C6-ceramide at a bactericidal concentrationactive antibacterial candidate under safety check

   Check whether bactericidal dosing causes significant host-cell toxicity.

   A host-compatibility check is performed after antibacterial activity is established to evaluate whether the active compound remains usable in a host-relevant context.

4. 4.
   Measure bacterial uptake of ceramide analogs by flow cytometry and CLSMassays used to quantify and visualize uptake

   Determine whether ceramide analogs are rapidly taken up by bacteria.

   After activity and host-compatibility are established, uptake measurements help connect antibacterial behavior to bacterial association.

5. 5.
   Visualize membrane distribution of ceramide analogs by CLSM and dSTORMimaging assays used for localization

   Determine spatial distribution of ceramide analogs in the bacterial membrane.

   Localization imaging follows uptake detection to provide higher-resolution spatial evidence about where the compounds accumulate.